Certara Expands Biosimulation Market with AI-Driven QSP Platform
Certara (Nasdaq: CERT) launched Certara IQ on October 30, 2025, an AI-powered Quantitative Systems Pharmacology (QSP) platform designed to scale biosimulation across drug discovery and development.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Certara (Nasdaq: CERT) launched Certara IQ on October 30, 2025, an AI-powered Quantitative Systems Pharmacology (QSP) platform designed to scale biosimulation across drug discovery and development.
The platform combines generative-AI, a library of pre-built scientifically validated QSP models and templates, a no-code “what-if” interface, and a high-performance simulation engine that the company says runs simulations thousands of times faster than traditional tools.
Certara IQ aims to improve model reproducibility, reduce manual work, shorten simulation times, and support dosing and patient-population decision making.
Positive
- Launch date: October 30, 2025
- AI-enabled QSP with generative-AI interface for model building
- Pre-built model library of scientifically validated QSP models and templates
- Simulation speed claimed to be thousands of times faster than traditional tools
- No-code “what-if” interface to accelerate dosing and feasibility analysis
- Market tailwind: QSP FDA submissions nearly doubled every 1.4 years since 2013
Negative
- None.
Details
News Market Reaction – CERT
On Oct 31, the first trading day after this news, CERT closed 2.38% above the previous close.
Data tracked by StockTitan Argus for the Oct 31 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Certara IQ™ integrates AI and biosimulation to accelerate R&D productivity, reduce risk, and deepen understanding of novel and complex therapies
RADNOR, Pa., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced the launch of Certara IQ, a scalable, AI-powered Quantitative Systems Pharmacology (QSP) solution.
QSP has rapidly become a cornerstone of modern drug discovery and development with QSP-based FDA submissions having nearly doubled every 1.4 years since 2013.1 QSP combines computational modeling and experimental data to examine how a drug interacts with biological systems and disease processes, enabling scientists to predict critical outcomes such as optimal dosing, therapeutic window, and ideal patient populations. These capabilities are especially critical for novel or complex modalities.
“Certara IQ represents the next step in making biosimulation a foundational capability across the entire drug discovery and development value chain,” said William F. Feehery, Chief Executive Officer. “By uniting AI, systems modeling and scientific expertise at scale, we’re enabling companies to make smarter portfolio decisions, reduce development risk, and accelerate the delivery of new therapies to patients.”
Certara IQ removes many of the computational and workflow challenges that have historically limited QSP adoption including minimal model reuse, long simulation times, complex coding environments, and a lack of standardization. Its AI-driven software reduces manual work and enhances reproducibility, making QSP modeling faster, easier, and more impactful. Certara IQ:
- Enhances model reproducibility and reusability through an intuitive, generative-AI supported interface for building and visualizing QSP models
- Accelerates model creation with a deep repository of scientifically validated and pre-built QSP models, workflows and report templates
- Reduces computational bottlenecks with a high-performance simulation engine that runs simulations thousands of times faster than traditional tools.
- Empowers decision making with a no-code interface for “what-if” analysis to assess feasibility, identify data gaps, and optimize dosing and drug properties quickly.
To learn more about Certara IQ, visit: https://www.certara.com/software/quantitative-systems-pharmacology/
About Certara
Certara accelerates medicines using proprietary biosimulation software, technology and services to transform traditional drug discovery and development. Its clients include more than 2,400 biopharmaceutical companies, academic institutions, and regulatory agencies across 70 countries. Visit us at www.certara.com.
Certara Contact:
Sheila Rocchio
sheila.rocchio@certara.com
Media Contact:
Alyssa Horowitz
certara@pancomm.com
___________________
1 Cucurull-Sanchez, L. An industry perspective on current QSP trends in drug development. J Pharmacokinet Pharmacodyn 51, 511–520 (2024). https://doi.org/10.1007/s10928-024-09905-y
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.